Gallagher Re’s analysis examines the financial impact of GLP-1 weight management drugs like Ozempic, Wegovy, and Mounjaro on employer-sponsored health plans, considering both rising prescription costs and potential health outcome improvements.
A new analysis from GoodRx reveals a decrease in commercial insurance coverage for GLP-1 medications, alongside increased utilization management, potentially hindering patient access to vital treatments.
